A key election promise to add more than 50 conditions to newborn testing nationally has turned out to be harder than first thought.
First opioids and now spinal cord stimulators. Should companies walk away from pain rather than risk more reputational damage?
The Reference Committee has laid out a bold plan for change, but not without expecting something in return from the medicines sector.
The committee has several co-dependent tests on its first agenda for 2024, but with no chair and a late meeting, will it lead to delays?
Timing for the government response to New Frontier report revealed as Mark Butler announces chair for ‘one stop shop’ trials body.
Five members including a Deputy Chair have departed the committee in recent months as its Chair’s term also nears an end.
Another industry association called for Mark Butler to broaden the scope of the review and grant it representation on the committee.
States agree on bloodspot screening list while the Commonwealth introduces a streamlined pathway for additional conditions to be considered.